109 related articles for article (PubMed ID: 35725938)
1. Up-regulation of POM121 is linked to prostate cancer aggressiveness and serves as a prognostic biomarker.
Becker F; Offermann A; Roesch MC; Joerg V; Roth D; Lubczyk V; Kuefer R; Sailer V; Kirfel J; Merseburger AS; Perner S
Urol Oncol; 2022 Aug; 40(8):380.e11-380.e18. PubMed ID: 35725938
[TBL] [Abstract][Full Text] [Related]
2. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer.
Becker F; Joerg V; Hupe MC; Roth D; Krupar R; Lubczyk V; Kuefer R; Sailer V; Duensing S; Kirfel J; Merseburger AS; Brägelmann J; Perner S; Offermann A
Int J Cancer; 2020 Jan; 146(2):577-588. PubMed ID: 31271443
[TBL] [Abstract][Full Text] [Related]
5. Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import.
Rodriguez-Bravo V; Pippa R; Song WM; Carceles-Cordon M; Dominguez-Andres A; Fujiwara N; Woo J; Koh AP; Ertel A; Lokareddy RK; Cuesta-Dominguez A; Kim RS; Rodriguez-Fernandez I; Li P; Gordon R; Hirschfield H; Prats JM; Reddy EP; Fatatis A; Petrylak DP; Gomella L; Kelly WK; Lowe SW; Knudsen KE; Galsky MD; Cingolani G; Lujambio A; Hoshida Y; Domingo-Domenech J
Cell; 2018 Aug; 174(5):1200-1215.e20. PubMed ID: 30100187
[TBL] [Abstract][Full Text] [Related]
6. TRIM24 as an independent prognostic biomarker for prostate cancer.
Offermann A; Roth D; Hupe MC; Hohensteiner S; Becker F; Joerg V; Carlsson J; Kuempers C; Ribbat-Idel J; Tharun L; Sailer V; Kirfel J; Svensson M; Andren O; Lubczyk V; Kuefer R; Merseburger AS; Perner S
Urol Oncol; 2019 Sep; 37(9):576.e1-576.e10. PubMed ID: 31178279
[TBL] [Abstract][Full Text] [Related]
7. POM121 overexpression is related to a poor prognosis in colorectal cancer.
Wang T; Sun H; Bao Y; En R; Tian Y; Zhao W; Jia L
Expert Rev Mol Diagn; 2020 Mar; 20(3):345-353. PubMed ID: 31858845
[No Abstract] [Full Text] [Related]
8. POM121 is a novel marker for predicting the prognosis of laryngeal cancer.
Zhao R; Tang G; Wang T; Zhang L; Wang W; Zhao Q; Zhao K
Histol Histopathol; 2020 Nov; 35(11):1285-1293. PubMed ID: 33016327
[TBL] [Abstract][Full Text] [Related]
9. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of LIMK1 expression in prostate cancer is correlated with poor pathological features, lymph node metastases and biochemical recurrence.
Huang JB; Wu YP; Lin YZ; Cai H; Chen SH; Sun XL; Li XD; Wei Y; Zheng QS; Xu N; Xue XY
J Cell Mol Med; 2020 Apr; 24(8):4698-4706. PubMed ID: 32168432
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.
Chen X; Bernemann C; Tolkach Y; Heller M; Nientiedt C; Falkenstein M; Herpel E; Jenzer M; Grüllich C; Jäger D; Sültmann H; Duensing A; Perner S; Cronauer MV; Stephan C; Debus J; Schrader AJ; Kristiansen G; Hohenfellner M; Duensing S
Urol Oncol; 2018 Apr; 36(4):161.e19-161.e30. PubMed ID: 29198908
[TBL] [Abstract][Full Text] [Related]
12. Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis.
Hupe MC; Philippi C; Roth D; Kümpers C; Ribbat-Idel J; Becker F; Joerg V; Duensing S; Lubczyk VH; Kirfel J; Sailer V; Kuefer R; Merseburger AS; Perner S; Offermann A
Front Oncol; 2018; 8():623. PubMed ID: 30619757
[No Abstract] [Full Text] [Related]
13. TWIST overexpression predicts biochemical recurrence-free survival in prostate cancer patients treated with radical prostatectomy.
Raatikainen S; Aaltomaa S; Palvimo JJ; Kärjä V; Soini Y
Scand J Urol; 2015 Feb; 49(1):51-7. PubMed ID: 24779451
[TBL] [Abstract][Full Text] [Related]
14. The prognosis value of EphA3 and the androgen receptor in prostate cancer treated with radical prostatectomy.
Duan X; Xu X; Yin B; Hong B; Liu W; Liu Q; Tao Z
J Clin Lab Anal; 2019 Jun; 33(5):e22871. PubMed ID: 30958616
[TBL] [Abstract][Full Text] [Related]
15. Clinical Significance of
Zhang S; Zheng C; Li D; Bei C; Zhang H; Tian R; Song X; Zhu X; Tan S
Genet Test Mol Biomarkers; 2020 Dec; 24(12):819-824. PubMed ID: 33296260
[No Abstract] [Full Text] [Related]
16. POM121 promotes proliferation and metastasis in non-small-cell lung cancer through TGF-β/SMAD and PI3K/AKT pathways.
Guan L; Zhang L; Wang T; Jia L; Zhang N; Yan H; Zhao K
Cancer Biomark; 2021; 32(3):293-302. PubMed ID: 34151840
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy.
Quinn DI; Henshall SM; Head DR; Golovsky D; Wilson JD; Brenner PC; Turner JJ; Delprado W; Finlayson JF; Stricker PD; Grygiel JJ; Sutherland RL
Cancer Res; 2000 Mar; 60(6):1585-94. PubMed ID: 10749127
[TBL] [Abstract][Full Text] [Related]
18. Increased nuclear factor erythroid 2-related factor 2 expression predicts worse prognosis of prostate cancer patients treated with radical prostatectomy.
Raatikainen S; Aaltomaa S; Kärjä V; Soini Y
Hum Pathol; 2014 Nov; 45(11):2211-7. PubMed ID: 25175169
[TBL] [Abstract][Full Text] [Related]
19. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.
Yu L; Toriseva M; Tuomala M; Seikkula H; Elo T; Tuomela J; Kallajoki M; Mirtti T; Taimen P; Boström PJ; Alanen K; Nurmi M; Nees M; Härkönen P
Int J Cancer; 2016 Jul; 139(1):140-52. PubMed ID: 26891277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
